This page shows the latest lapatinib news and features for those working in and with pharma, biotech and healthcare.
A number of metastatic breast cancer treatments have been rejected by the UK cost-effectiveness watchdog over the last few years, including GlaxoSmithKline's Tyverb (lapatinib) and Roche's Herceptin (trastuzumab),
For advanced breast cancer, Novartis's newly acquired breast cancer drug Tyverb (lapatinib) scores five, but there are four drugs that score three or less, including Eisai's breast cancer medicine
Details of the asset swap were first revealed last April. Novartis claims ownership of several marketed products - including kidney cancer therapy Votrient (pazopanib) and Tyverb (lapatinib) for breast cancer - and also
eribulin), GSK's Tyverb (lapatinib) and Novartis' Afinitor (everolimus)), were to be de-listed. ... GlaxoSmithKline's Tyverb (lapatinib):. treatment of advanced breast cancer. GlaxoSmithKline's Arzerra (ofatumumab):.
GSK. Arzerra (ofatumumab). Chronic lymphocytic leukaemia. Tyverb (lapatinib). Breast cancer. Votrient (pazopanib).
Chronic lymphocytic leukaemia. GlaxoSmithKline. Arzerra (ofatumumab) . Chronic lymphocytic leukaemia. Tyverb (lapatinib).
More from news
Approximately 2 fully matching, plus 46 partially matching documents found.
While Kadcyla demonstrated superior efficacy over Tykerb. 6. (Lapatinib) in 2.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...